Johnson & Johnson (JNJ): Is the 40% Year-to-Date Rally Just Catch-Up to Fair Value?

Johnson & Johnson (JNJ) keeps grinding higher, and with the stock up roughly 14% over the past 3 months and nearly 40% year to date, investors are asking what is driving the momentum.

See our latest analysis for Johnson & Johnson.

That surge has been backed by a solid 8% 1 month share price return and a powerful near 40% year to date share price gain, while a 5 year total shareholder return of about 56% shows momentum has been building, not fading, for long term holders.

If J&J’s run has you thinking more broadly about healthcare leaders, it could be a smart moment to explore other potential winners across healthcare stocks.

Yet with Johnson & Johnson now trading just below analyst targets but still showing a hefty intrinsic value gap, the key question is whether the market is overlooking upside or is already pricing in years of future growth.

Most Popular Narrative Narrative: 50% Undervalued

With Johnson & Johnson closing at $201.62 against a narrative fair value near $202.54, the story frames today’s rally as only a partial re rating.

Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.

Read the complete narrative.

Want to see what is hiding behind this optimism, a slow burn revenue build, a richer profit profile, and a premium future earnings multiple, all modeled out?

Result: Fair Value of $202.54 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing talc litigation and revenue pressure from key loss of exclusivity events could quickly challenge the case for sustained multiple expansion.

Find out about the key risks to this Johnson & Johnson narrative.

Build Your Own Johnson & Johnson Narrative

If you see the story differently or prefer to dig into the numbers yourself, you can build a personalized view in just minutes: Do it your way.

A great starting point for your Johnson & Johnson research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Use the Simply Wall Street Screener now to act on fresh opportunities, so you are not watching from the sidelines while others capture the upside.

• Capitalize on potential bargains by targeting companies trading below intrinsic value with these 902 undervalued stocks based on cash flows before the market closes the gap.
• Position yourself for potential innovation in automation, data, and algorithms by focusing on companies in this space through these 27 AI penny stocks.
• Explore potential income streams by focusing on dependable payers using these 15 dividend stocks with yields > 3% while yields remain attractive.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com